MapLight Therapeutics, a clinical-stage biotech based in Redwood City, California, is seeking a valuation of up to US$704.3 million in its planned US IPO.

The company aims to raise US$250.8 million by offering 14.8 million shares at US$17 each, with plans to list on Nasdaq under the symbol MPLT.

MapLight develops treatments for central nervous system disorders, including schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, and Parkinson’s disease.

Its current pipeline features ML-007C-MA for schizophrenia and Alzheimer’s psychosis, and ML-004 for autism-related social difficulties.

The company posted a net loss of US$52.2 million for the first half of 2025, compared to a US$37.3 million loss in the same period last year.

In July, MapLight raised US$372.5 million in a funding round co-led by Forbion and Life Sciences at Goldman Sachs Alternatives.

Morgan Stanley, Jefferies, Leerink Partners, and Stifel are underwriting the IPO.

🔗 Source: Reuters